Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2014, Article ID 984067, 5 pages
http://dx.doi.org/10.1155/2014/984067
Research Article

Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study

1Broomfield Hospital, Court Road, Chelmsford, Essex CM1 7ET, UK
2Rivers Hospital, High Wych Road, Sawbridgeworth Hertfordshire CM21 0HH, UK
3Strategen Limited, 2 & 3 Stable Court, Herriard Park Estate, Herriard, Basingstoke RG25 2PL, UK

Received 1 October 2013; Accepted 10 December 2013; Published 12 January 2014

Academic Editor: Ian S. Fentiman

Copyright © 2014 Neville Davidson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. W. Jones, M. J. Haykowsky, J. J. Swartz, P. S. Douglas, and J. R. Mackey, “Early breast cancer therapy and cardiovascular injury,” Journal of the American College of Cardiology, vol. 50, no. 15, pp. 1435–1441, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. A. M. Rahman, S. W. Yusuf, and M. S. Ewer, “Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation,” International Journal of Nanomedicine, vol. 2, pp. 567–583, 2007. View at Google Scholar
  3. G. Batist, G. Ramakrishnan, C. S. Rao et al., “Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer,” Journal of Clinical Oncology, vol. 19, no. 5, pp. 1444–1454, 2001. View at Google Scholar · View at Scopus
  4. L. Harris, G. Batist, R. Belt et al., “Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma,” Cancer, vol. 94, no. 1, pp. 25–36, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Chan, N. Davidson, E. Juozaityte et al., “Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer,” Annals of Oncology, vol. 15, no. 10, pp. 1527–1534, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Batist, L. Harris, N. Azarnia, L. W. Lee, and P. Daza-Ramirez, “Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis,” Anti-Cancer Drugs, vol. 17, no. 5, pp. 587–595, 2006. View at Google Scholar · View at Scopus
  7. Myocet [UK Prescribing Information], Cephalon, Welwyn Garden City, UK, 2011, http://www.medicines.org.uk/.
  8. P. Schmid, J. Krocker, C. Jehn et al., “Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial,” Annals of Oncology, vol. 16, no. 10, pp. 1624–1631, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Antón, A. Ruiz-Simon, A. Plazaola et al., “Phase II study of a 3-weekly liposome-encapsulated doxorubicin/docetaxel/pegfligrastrim in combination with weekly trastuzumab as primary treatment in Her2 positive (Her2+) early stage breast cancer patients (II-IIIa). GEICAM 2003-03 Study,” Cancer Research, vol. 69, supplement 2, p. 511, 2009. View at Google Scholar
  10. British Society of Echocardiography Education Committee, “Echocardiography: Guidelines for Chamber Quantification,” http://www.bhf.org.uk/publications/view-publication.aspx?ps=1001601.
  11. “Defining research. National Research Ethics Service. Ref: 0987,” December 2009, http://www.nres.nhs.uk/applications/is-your-project-research/.
  12. A. Seidman, C. Hudis, M. Kathryn Pierri et al., “Cardiac dysfunction in the trastuzumab clinical trials experience,” Journal of Clinical Oncology, vol. 20, no. 5, pp. 1215–1221, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” The New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. Clinicaltrials.gov, “Combination therapy with Myocet (doxorubicin HCl liposome for injection) in patients with HER2-positive breast cancer,” http://www.clinicaltrials.gov/ct2/show/NCT000712881.
  15. J. Cortes, S. DiCosimo, M. A. Climent et al., “Nonpegylated liposomal doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase l/ll study,” Clinical Cancer Research, vol. 15, no. 1, pp. 307–314, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Venturini, C. Bighin, F. Puglisi et al., “A multicentre phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer,” Breast, vol. 19, no. 5, pp. 333–338, 2010. View at Publisher · View at Google Scholar · View at Scopus